For example, approximately 15 years ago, several small studies of erythropoietin demonstrated mixed effects for CRCI,6 but there have been no additional studies after the FDA issued a warning about it increasing thromboembolic risk in cancer patients.31 This evidence concerns the gene EPO and cancer.